A rare case of eye complications of gastric stromal tumor treatment using imatinib mesylate
https://doi.org/10.21516/2072-0076-2020-13-3-88-91
Abstract
Purpose: to describe a clinical case of ocular complications of gastric stromal tumor treatment with imatinib mesylate.
Material and methods. A patient aged 78 was examined by general ophthalmologic and instrumental methods, including ultrasound and spectral optical coherence tomography (SOCT).
Results. Ophthalmoscopy helped diagnose a blunted foveal reflex of the right eye. In the left eye, fuzzy boundaries of the optic disc edema and the macular reflex, the presence of gray-yellow foci of an irregular shape with even distinct boundaries in the paramacular zone were revealed. In the lower part of the left eye fundus, a weakly pigmented gray-yellow focus with uneven indistinct boundaries and an uneven surface was to be seen. SOCT showed in the right eye a retinal edema in the macula and paramacular zones and an epiretinal membrane. In the left eye, SOCT showed vitreoretinal tractions and retinal edema on the edges of the optic nerve; in the paramacular zone and in the inner parts of the fundus, vitreoretinal tractions, epiretinal fibrosis, retinal edema was observed whilst in the lower parts of the fundus complete destruction of all retinal layers due to the hyperreflective focus with a small-shaped inner contour, an even choroidal profile with thinning of the choroid, vitreoretinal tractions, and epiretinal membrane in the left eye could be seen.
Conclusions. The clinical case of eye complications of imatinib mesylate in the treatment of gastric stromal tumor necessitates an interdisciplinary integrated approach (involving an oncologist and an ocular oncologist) in the diagnosis and treatment of eye tumors. A complex of instrumental methods of diagnostics of eye fundus diseases involving additional refinement methods (SOCT) ensures differential diagnosis of retinopathy during the chemotherapy, secondary metastatic involvement, and vitreoretinal pathology of a different pathogenetic etiology. Early diagnosis facilitates providing adequate treatment aimed at preserving the patient’s vision, the eye, and life.
About the Authors
E. B. Myakoshina
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Elena B. Myakoshina — Cand. of Med. Sci., researcher, department of ophthalmooncology and radiology.
105062, 14/19, Sadovaya-Chernogryazskaya st., Moscow
S. V. Saakyan
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Svetlana V. Saakyan — Dr. of Med. Sci., Professor, head of the department of ophthalmooncology and radiology.
105062, 14/19, Sadovaya-Chernogryazskaya st., Moscow
References
1. Roskoski R. A historical overview of protein kinases and their targeted small molecule inhibitors. Pharmacological Res. 2015; 100: 1–23. doi:http://dx.doi.org/10.1016/j.phrs.2015.07.010
2. Savage D.G., Antman K.H. Imatinib mesylate – a new oral targeted therapy. N. Engl. J. Med. 2002; 346: 683–93. doi: 10.1056/NEJMra013339
3. Ami E.B., Demetri G.D. A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor. Expert Opinion on Drug Safety. 2016; 15 (4): 571–8.
4. Chen H.X., Cleck J.N. Adverse effects of anticancer agents that target the VEGF pathway. Nat. Rev. Clin. Oncol. 2009; 6 (8): 465–77. doi: 10.1038/nrclinonc.2009.94
5. Shimazaki C., Ochiai N., Uchida R., et al. Intramuscular edema as a complication of treatment with imatinib. Leukemia. 2003; 17: 804–5. doi:10.1038/sj.leu.2402868
6. Ebnoether M., Stentoft J., Ford J., Buhl L., Gratwohl A. Cerebral oedema as a possible complication of treatment with imatinib. Lancet. 2002; 359: 1751–2. doi: 10.1016/S0140-6736(02)08616-6
7. Kusumi E., Arakawa A., Kami M., et al. Visual disturbance due to retinal edema as a complication of imatinib. Leukemia. 2004; 18: 1138–9. doi: 10.1038/sj.leu.2403364
8. Fraunfelder F.W., Solomon J., Druker B.J., Esmaeli B., Kuyl J. Ocular side-effects associated with imatinib mesylate (Gleevec). J. Ocul. Pharmacol. Ther. 2003; 19: 371–5. doi: 10.1089/108076803322279426
9. Crystal D., Shenouda-Awad N., Haskes C., Wrzesinski S. Imatinib Mesylate (Gleevec) induced unilateral optic disc edema. Optometry and Vision Science. Oct 2012; 89 (10): 16–22. doi: 10.1097/OPX.0b013e318269111d
10. Pietras K., Ostman A., Sjoquist M., et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 2001; 61: 2929–34. PMID: 11306470
11. Lindahl P., Johansson B.R., Leveen P., Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science. 1997; 277: 242–5. doi: 10.1126/science.277.5323.242
12. Koleske A.J., Gifford A.M., Scott M.L., et al. Essential roles for the Abl and Arg tyrosine kinases in neurulation. Neuron. 1998 Dec; 21 (6): 1259–72. doi: 10.1016/s0896-6273(00)80646-7
13. Robbins S.G., Mixon R.N., Wilson D.J., et al. Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases. Invest. Ophthalmol. Vis. Sci. 1994 Sep; 35: 3649–63. PMID:8088954
14. Saakyan S.V., Myakoshina E.B., Yurovskaya N.N., Ryabina M.V. Choroidal metastatic carcinoma: two clinical cases.Vestnik oftal'mologii. 2013; 2: 58–62 (in Russian).
15. Neroev V.V. Modern aspects of the treatment of diabetic macular edema. Russian ophthalmological journal. 2012; 5 (1): 4–7 (in Russian).
Review
For citations:
Myakoshina E.B., Saakyan S.V. A rare case of eye complications of gastric stromal tumor treatment using imatinib mesylate. Russian Ophthalmological Journal. 2020;13(3):88-91. (In Russ.) https://doi.org/10.21516/2072-0076-2020-13-3-88-91
Views:
740
Email this article 